Raymond Lin,Seethalakshmi Viswanathan,Nikki L Wong
{"title":"非诺贝特诱导的渗透性肾病:急性肾损伤的新机制。","authors":"Raymond Lin,Seethalakshmi Viswanathan,Nikki L Wong","doi":"10.1053/j.ajkd.2025.03.019","DOIUrl":null,"url":null,"abstract":"Fibrates are a commonly utilized medication in the management of dyslipidaemia and cardiovascular risk. These agents have a well-documented association with reversible elevations in serum creatinine and in some instances acute kidney injury. The mechanism underlying the renal effects of fibrates are currently not well-understood. We describe a case of acute kidney injury in a patient who was administered an unadjusted dose of fenofibrate in the setting of severe renal impairment. Kidney biopsy demonstrated extensive isometric vacuolization within tubular epithelial cells consistent with osmotic-type injury. Fenofibrate in this case was the likely causative agent based on the temporal relationship of drug administration and acute kidney injury. The acute kidney injury also recovered over a timeframe consistent with the known half-life of the drug metabolite. There were no other drugs, extremes instances of hyperglycaemia, or intravenous agents administered to account for the biopsy findings. This case demonstrates a potential novel mechanism of fenofibrate-associated acute kidney injury with osmotic nephropathy. We review the current understanding of the effects of fenofibrate on the kidney and possible pathogenesis of osmotic nephropathy.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"40 1","pages":""},"PeriodicalIF":9.4000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fenofibrate-Induced Osmotic Nephropathy: A Novel Mechanism of Acute Kidney Injury.\",\"authors\":\"Raymond Lin,Seethalakshmi Viswanathan,Nikki L Wong\",\"doi\":\"10.1053/j.ajkd.2025.03.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Fibrates are a commonly utilized medication in the management of dyslipidaemia and cardiovascular risk. These agents have a well-documented association with reversible elevations in serum creatinine and in some instances acute kidney injury. The mechanism underlying the renal effects of fibrates are currently not well-understood. We describe a case of acute kidney injury in a patient who was administered an unadjusted dose of fenofibrate in the setting of severe renal impairment. Kidney biopsy demonstrated extensive isometric vacuolization within tubular epithelial cells consistent with osmotic-type injury. Fenofibrate in this case was the likely causative agent based on the temporal relationship of drug administration and acute kidney injury. The acute kidney injury also recovered over a timeframe consistent with the known half-life of the drug metabolite. There were no other drugs, extremes instances of hyperglycaemia, or intravenous agents administered to account for the biopsy findings. This case demonstrates a potential novel mechanism of fenofibrate-associated acute kidney injury with osmotic nephropathy. We review the current understanding of the effects of fenofibrate on the kidney and possible pathogenesis of osmotic nephropathy.\",\"PeriodicalId\":7419,\"journal\":{\"name\":\"American Journal of Kidney Diseases\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Kidney Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1053/j.ajkd.2025.03.019\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Kidney Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.ajkd.2025.03.019","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Fenofibrate-Induced Osmotic Nephropathy: A Novel Mechanism of Acute Kidney Injury.
Fibrates are a commonly utilized medication in the management of dyslipidaemia and cardiovascular risk. These agents have a well-documented association with reversible elevations in serum creatinine and in some instances acute kidney injury. The mechanism underlying the renal effects of fibrates are currently not well-understood. We describe a case of acute kidney injury in a patient who was administered an unadjusted dose of fenofibrate in the setting of severe renal impairment. Kidney biopsy demonstrated extensive isometric vacuolization within tubular epithelial cells consistent with osmotic-type injury. Fenofibrate in this case was the likely causative agent based on the temporal relationship of drug administration and acute kidney injury. The acute kidney injury also recovered over a timeframe consistent with the known half-life of the drug metabolite. There were no other drugs, extremes instances of hyperglycaemia, or intravenous agents administered to account for the biopsy findings. This case demonstrates a potential novel mechanism of fenofibrate-associated acute kidney injury with osmotic nephropathy. We review the current understanding of the effects of fenofibrate on the kidney and possible pathogenesis of osmotic nephropathy.
期刊介绍:
The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.